Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy.
Zangrilli A, Caldarola G, Bernardini N, Bavetta M, Graceffa D, Bonifati C, Cantoresi F, Faleri S, Giordano D, Mariani M, Micheli A, Moretta G, Pirro F, Pagnanelli G, Panasiti V, Provini A, Richetta A, Sacchelli L, Bianchi L, Peris K. Zangrilli A, et al. Among authors: provini a. Expert Opin Biol Ther. 2021 Sep;21(9):1291-1298. doi: 10.1080/14712598.2021.1948530. Epub 2021 Jul 18. Expert Opin Biol Ther. 2021. PMID: 34278889
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
Caldarola G, Zangrilli A, Bernardini N, Bavetta M, De Simone C, Graceffa D, Bonifati C, Faleri S, Giordano D, Mariani M, Micheli A, Moretta G, Pagnanelli G, Panasiti V, Provini A, Richetta A, Peris K, Bianchi L. Caldarola G, et al. Among authors: provini a. Dermatol Ther. 2022 Jun;35(6):e15489. doi: 10.1111/dth.15489. Epub 2022 Apr 13. Dermatol Ther. 2022. PMID: 35385202 Free PMC article.
Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study.
Graceffa D, Zangrilli A, Caldarola G, Lora V, Orsini D, Moretta G, Pagnanelli G, Provini A, Masini C, Bavetta M, Giordano D, Richetta A, Tolino E, Bianchi L, Peris K, Sperati F, Bonifati C. Graceffa D, et al. Among authors: provini a. Int J Dermatol. 2024 Oct;63(10):1383-1391. doi: 10.1111/ijd.17156. Epub 2024 Apr 7. Int J Dermatol. 2024. PMID: 38584311
A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis?
Scala E, Madonna S, Abeni D, Cecchi L, Cocuroccia B, Dattolo A, Moretta G, Provini A, Russo F, Sordi D, Pallotta S, Galluzzo M, Talamonti M, Villella V, Giani M, Caprini E, Albanesi C, Villalta D, Asero R, Matricardi PM. Scala E, et al. Among authors: provini a. Allergy. 2024 Dec;79(12):3415-3429. doi: 10.1111/all.16377. Epub 2024 Nov 4. Allergy. 2024. PMID: 39495073
Clinical severity measures and patient-reported outcomes in atopic dermatitis.
Sampogna F, Dattolo A, Cocuroccia B, Moretta G, Provini A, Sordi D, Fusari R, Melo Salcedo N, Abeni D. Sampogna F, et al. Among authors: provini a. J Eur Acad Dermatol Venereol. 2024 Jun;38(6):e545-e547. doi: 10.1111/jdv.19753. Epub 2023 Dec 29. J Eur Acad Dermatol Venereol. 2024. PMID: 38158340 No abstract available.
Development of bullous pemphigoid in junctional epidermolysis bullosa.
Fania L, Provini A, Salemme A, Sinagra JL, Guerra L, Mazzanti C, Didona B, Castiglia D, Di Zenzo G. Fania L, et al. Among authors: provini a. J Eur Acad Dermatol Venereol. 2020 Mar;34(3):e146-e148. doi: 10.1111/jdv.16057. Epub 2020 Feb 13. J Eur Acad Dermatol Venereol. 2020. PMID: 31709656 No abstract available.
Eosinophilic annular erythema: Report of four cases.
Fania L, Provini A, Rota L, Mazzanti C, RIcci F, Panebianco A, Ricci F, Ruggeri S, Didona B. Fania L, et al. Among authors: provini a. Dermatol Ther. 2020 Nov;33(6):e14369. doi: 10.1111/dth.14369. Epub 2020 Oct 16. Dermatol Ther. 2020. PMID: 33025705 No abstract available.
62 results